n">(Reuters) - Cytori Therapeutics Inc said it has suspended enrollments in two trials of its experimental cell therapy for heart failure patients after a safety review.
The company's shares fell 13 percent in extended trade.
Cerebrovascular events - those related to blood vessels in the brain - were reported in studies to evaluate safety and feasibility of adipose-derived regenerative cells in patients with ischemic heart disease, the company said.
Symptoms occurred in three patients, the company said. Two patients' symptoms fully resolved within a short period, it said, while the third has experienced a substantial resolution.
Cytori's shares closed at $2.10 on the Nasdaq on Tuesday.
(Reporting by Shailesh Kuber; Editing by Ted Kerr)
Images from the Ebola outbreak responsible for the deaths of hundreds across Guinea, Liberia and Sierra Leone. Slideshow
This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.